Our top oncology content of 2017 – a note from the Editor

Welcome to 2018 on Oncology Central! These past 12 months, we have been busier than ever producing content for you, our amazing audience. To kick off the New Year we are taking the opportunity to look back on the hottest themes across the site in 2017 including trends, developments and popular posts.

As per previous years, immuno-oncology was a major topic in 2017. To help shed light on the current status of immunotherapy in the clinic we hosted a free 2-day online educational symposium in June. Chaired by Angus Dagleish and with speakers such as James Gulley, Roy Herbst and Marc Ernstoff; the insightful event covered key areas such as rational combinations of immunotherapies, management of therapy-related toxicities and asked what is next for immuno-oncology. You can watch all of the talks on demand here.

Over the course of the year we also featured many immunotherapy-related exclusive pieces to help you keep up to date with this rapidly evolving field. These ranged from news exploring the biology of the PDL-1 pathway, key drug approvals (including nivolumab for NSCLC) and over-arching interviews with key opinion leaders in the field such as James Gulley.

Another hot topic of 2017 was genetics; to provide you with insider details of the latest developments in cancer genetics we spoke with Illumina’s Chief Scientist, David Bentley about the implications the 100,000 Genomes Project for rare genetic diseases and cancer. Later in the year we also covered a hugely popular breast cancer genetics story when researchers unearthed 72 new genetic variants responsible for increasing the risk of breast cancer.

To help provide you with a fuller picture of the current status of breast cancer we went on to explore breast cancer through an infographic, a motion-graphics video with Macmillan Consultant Nurse Victoria Harmer and our editorial that rounded up the top 5 breast cancer advancements of 2017; highlights include pre-pectoral implants, PARP inhibitors and CDK4/6 inhibitors.

These are just some of the highlights of the last 12 months on Oncology Central. As always, thanks for reading, and I look forward to sharing many more with you all in 2018 as we continue to advance oncology together.

Best wishes,

Jade Parker 

Editor, Oncology Central

Interested in more top content? View more in key topic areas now including immunotherapy, breast cancer, colorectal cancer, biomarkers and personalized medicine.

Like what you see? Become a member FREE of charge for full access to all features, as well as complimentary access to our eight partnered journals: Breast Cancer Management, Lung Cancer Management, Colorectal Cancer, CNS Oncology and many more.